Answers are grounded in this paper and cite their sources.
Currently, dipeptidyl peptidase-4 inhibitors (gliptins) consistently occupy an increasingly important place in the arsenal of endocrinologists worldwide and are considered one of the most promising classes of hypoglycemic agents. According to the results of numerous studies among representatives of this group, vildagliptin demonstrates the greatest efficacy and safety in the treatment of type 2 diabetes mellitus, which, in addition to its sugar-lowering effect, has a positive effect on the cardiovascular system in the long term, has a beneficial effect on blood pressure, exhibits cardioprotective properties, is well tolerated by patients and has a low risk of hypoglycemia. These characteristics allow us to recommend vildagliptin for the treatment of patients with a wide range of comorbidities, including the elderly and senile.
No takes yet. Share an insight, caveat, or question.
T. Yu. Demidova (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: